Le Lézard
Classified in: Health
Subject: TRI

Study on New Treatments for Knee Arthritis Pain Now Enrolling New Patients


DALLAS, Jan. 20, 2020 /PRNewswire/ -- The Texas Orthobiologic Institute today announced a new clinical study evaluating three nonsurgical treatment protocols for minimizing pain and dysfunction for patients with knee arthritis. The study is called the HYP study and will evaluate viscosupplementation and platelet-rich plasma (PRP)  treatments. The HYP study will be randomized and double-blinded in order to provide a very high level of evidence.  Patients will be assigned to one of three treatment groups: viscosupplementation, PRP, or a combination of viscosupplementation and PRP. The study director is a board-certified orthopedic surgeon, Don Buford, MD, RMSK, who anticipates enrolling a total of 150 patients with knee arthritis into the HYP study. The study does not involve surgery and the treatments are all injections that will be done in the office. Both viscosupplementation and PRP have been shown to be safe therapies for knee arthritis, however, their combination has not been studied in a rigorous treatment protocol to date.

The Texas Orthobiologic Institute was founded to evaluate and use non-narcotic, nonsurgical treatments to help minimize patient pain and dysfunction from orthopedic conditions like arthritis. The Institute relies on evidence-based, regulatory-compliant treatment protocols, and the HYP study will be another example of the Institute's focus on improving clinical evidence for orthobiologic treatments in orthopedics.

There is no additional patient cost to be evaluated for enrollment in the study. "Our belief is that patients helping to contribute to medical research by participating in studies should not have to pay," said Don Buford, MD. The Texas Orthobiologic Institute expects to enroll patients through 2020 and to follow patients in the study for one year after treatment.

"Knee arthritis is a significant U.S. health concern that causes pain and disability. The USA spends millions of dollars a year on medications, injections, and surgeries to minimize pain and disability from knee arthritis. Our study is designed to show which is the best injection protocol using viscosupplementation and platelet-rich plasma in a way that has not been studied previously," said Don Buford, MD, the Founder of the Texas Orthobiologic Institute.

For additional information, the Study Coordinator can be reached at 877-211-4471

Media Contact:

Don Buford, MD

Phone: 214-924-9242

Email: [email protected]

Related Images

texas-orthobiologic-institute.png
Texas Orthobiologic Institute

SOURCE The Texas Orthobiologic Institute


These press releases may also interest you

at 08:45
Change Your Brain Foundation announced today it has been named a "2024 Top-Rated Nonprofit" by GreatNonprofits, the leading website for community recommendations of charities and nonprofits. Change Your Brain Foundation, established in 2008 by...

at 08:44
Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features...

at 08:42
It's no secret that if a person is healthy, they can do more than just survive. A healthy individual can have more life experiences, engage in more activities, and enjoy a more fulfilling quality of life. This larger goal of a healthy life well lived...

at 08:41
Wound healing can be a long and complicated process. Along with the healing itself, patients must consider factors such as a clean environment and consistent care. Quality of life can also be impacted by something as simple as unpleasant smells...

at 08:41
In a transformative approach to combating human trafficking in the United States, Safe House Project is revolutionizing the fight against this pervasive crime. By equipping hundreds of thousands of individuals across the nation with the tools to...

at 08:40
The "Global Cell Counting Market: Analysis By Product, By Application, By End-User, By Region Size, Trends and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The global cell counting market was valued at US$9.98...



News published on and distributed by: